Company profile
Bone Biologics Corporation
NASDAQ: BBLG · Healthcare · Biotechnology
#153 of 1,422 Healthcare companies by revenue41st-percentile growth
EA Score
45DFH 59DQ 23GM 61SS 17
v0.1 · 65/100 weight · provisional
↑ growth stability, balance-sheet leverage · ↓ workforce scale, listing tenure
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$3.1M
Employees
2
as of 2026-08-24
Market cap
$1.1M
as of 2026-08-24
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.1B$1.1B2020
Net income-$3.1M-$3.1M2025
Operating income-$3.2M-$3.2M2025
Total assets$5.8M$5.8M2025
Liabilities$418.6k$418.6k2025
Equity$5.4M$5.4M2025
Revenue trend
FY2017 – FY2020 · USD
FY17
FY18
FY19
FY20
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Bone Biologics Corporation’s revenue?
Bone Biologics Corporation booked $1.1B in FY2020 revenue, growing 0.0% year over year — about the middle of the pack among Healthcare companies we track, at a -0.3% net margin.
Peers · Healthcare
Prestige Consumer Healthcare Inc.79B+Embecta Corp.67BACADIA Pharmaceuticals Inc.82B+Tandem Diabetes Care, Inc.67BWELL Health Technologies Corp.71BGuardant Health, Inc.65BNeighbors
Middlesex →Key facts
CEOJeffrey Frelick
SectorHealthcare
IndustryBiotechnology
HeadquartersBurlington, MA
ExchangeNASDAQ: BBLG
Employees2
IPO date2021-10-13
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.